Skip to main content

Influenza

Featured Article
Gregg Sylvester, MD, MPH, chief medical officer, Seqirus, explains why the use of Fluad (Influenza Vaccine, Adjuvanted) was more effective than non-adjuvanted standard dose trivalent influenza…
“Reports of low influenza activity thus far have eased the anxieties and fears of many individuals during this ongoing COVID-19 pandemic,” says Yvette C Terrie, BS Pharm, RPh, consultant pharmacist…

Insights

Gregg Sylvester, MD, MPH, chief medical officer, and David Ross, vice president, commercial operations for North America, both at Seqirus, discuss the recent FDA approval for Flucelvax Quadrivalent, explain what the expanded indication means for…
“Reports of low influenza activity thus far have eased the anxieties and fears of many individuals during this ongoing COVID-19 pandemic,” says Yvette C Terrie, BS Pharm, RPh, consultant pharmacist. “Many individuals including HCPs are wondering if…
“Pharmacists are well positioned to improve vaccination rates and can act as advocates, educators, identifiers, and immunizers,” stresses Yvette C Terrie, BS Pharm, RPh, consultant pharmacist.

Interactive Features

Gregg Sylvester, MD, MPH, chief medical officer, Seqirus, explains why the use of Fluad (Influenza Vaccine, Adjuvanted) was more effective than non-adjuvanted standard dose trivalent influenza vaccine for reducing the risk of all-cause…
Back to Top